The R&D Tax Credit in 2026: What Business Owners Need to Know Now

 

If you run a business that develops new products, improves processes, or writes software, you may be sitting on a tax benefit you've never claimed or one you're claiming incorrectly. The federal R&D tax credit is one of the most valuable, and most misunderstood, incentives in the tax code. And thanks to a major law change in 2025, the calculus around it just shifted again.

 

Here's a practical rundown of what the credit is, who actually qualifies, and why the rules around it look different than they did even two years ago.

 

What the R&D Credit Actually Is

 

The R&D credit is a dollar-for-dollar reduction in tax liability for money spent on qualifying research activities. Unlike a deduction, which only reduces taxable income, a credit reduces the tax bill directly, which makes it considerably more valuable per dollar spent.

 

Despite the name, you don't need a lab coat or a patent to qualify. The credit was designed broadly, and in practice it reaches far beyond what most business owners think of as "research and development."

 

The Four-Part Test

 

To qualify as "qualified research", an activity generally has to satisfy four requirements:

 

• Permitted purpose — The activity aims to create or improve a business component's function, performance, reliability, or quality (a product, process, software, formula, or technique).

 

• Technological in nature — The work relies on principles of physical or biological science, engineering, or computer science.

 

• Elimination of uncertainty — At the outset, there's uncertainty about the capability, method, or design of the improvement.

 

• Process of experimentation — The work involves evaluating alternatives through modeling, simulation, systematic trial and error, or similar methods.

 

Importantly, the taxpayer doesn't need to succeed. A failed prototype or an abandoned software feature can still generate qualifying expenses, as long as the process itself meets the test.

 

Who This Actually Applies To

 

The industries that most commonly claim the credit include:

 

• Software and technology — new features, architecture changes, performance improvements, integrations

 

• Manufacturing — new product lines, tooling, process improvements, automation

 

• Engineering and architecture — design work involving technical uncertainty

 

• Food and beverage — new formulations, shelf-life testing, process changes

 

• Life sciences and biotech — the traditional face of the credit, but far from the only qualifying industry

 

A common misconception is that only companies with a dedicated "R&D department" qualify. In reality, a lot of qualifying work happens inside engineering, product, or operations teams that would never describe what they do as research.

 

What Counts as a Qualified Research Expense (QRE)

 

Once you've identified qualifying activities, the credit is calculated based on:

 

• Wages for employees directly performing, supervising, or supporting the research

 

• Supplies consumed in the research process (not capital equipment)

 

• Contract research — generally 65% of amounts paid to third parties for qualifying work performed on the taxpayer's behalf

 

• Cloud computing costs for hosting used directly in research, under certain conditions

 

Getting this allocation right, separating qualifying time and cost from ordinary business activity is where most of the real work (and most audit risk) lives.

 

The Big Wrinkle: Section 174 Went Through Whiplash

 

This is the part of the story that's changed the R&D tax landscape more than anything else in the last decade, and it's worth understanding even if you already know the basic credit mechanics.

 

Before 2022: Businesses could deduct R&D expenses immediately, in the year incurred.

 

2022–2024: The Tax Cuts and Jobs Act's amortization requirement kicked in. Suddenly, domestic R&D costs had to be capitalized and spread over five years (fifteen years for research conducted outside the U.S.), even though the R&D credit rules didn't change. This created a painful mismatch — companies were paying tax on income that included R&D costs they couldn't fully deduct yet, which hit cash-strapped and growth-stage companies especially hard.

 

2025 onward: The One Big Beautiful Bill Act (OBBBA) enacted new Section 174A, which permanently allows taxpayers to fully expense domestic research or experimental expenditures paid or incurred in taxable years beginning after Dec. 31, 2024.

 

In plain terms: immediate expensing for U.S.-based R&D is back, and this time it's permanent rather than a temporary provision on a countdown clock.

 

A few details matter here:

 

Foreign R&D didn't get the same relief. Foreign R&E expenses remain subject to 15-year amortization, and the OBBBA repeal applied only to domestic R&E under new Section 174A. Companies with offshore development teams need to keep tracking domestic versus foreign costs separately, this is a real planning consideration for any business with cross-border engineering.

 

There was retroactive relief for small businesses, but the window already closed. Only businesses meeting the $31 million gross receipts test could amend prior years under the OBBBA retroactive election, and the election window closed on July 6, 2026. If your business fit that profile and didn't act, that particular door has now shut, though standard amended-return rules and other planning avenues may still be relevant depending on your facts.

 

Larger businesses had a separate, narrower option: companies above the $31 million threshold could not use the retroactive election, but had a one-time election to accelerate the recovery of any remaining unamortized 2022–2024 domestic R&E expenses entirely in 2025, or split between 2025 and 2026.

 

Why This Makes the Credit More Valuable, Not Less

 

There's a subtlety worth flagging: Section 174 (the deduction) and Section 41 (the credit) interact. Section 280C(c) requires that any deduction under Section 174A be reduced by any R&D credit taken under Section 41, unless the taxpayer elects to reduce the R&D credit instead. That trade-off has always existed, but with amortization drag now gone, the practical value of pairing the credit with immediate expensing has improved. As one industry analysis put it plainly: skipping the credit only forfeits the credit benefit, and OBBBA improves the value of the credit by removing the amortization drag, so companies should generally claim both the immediate deduction and the credit.

 

Common Pitfalls

 

A few patterns show up again and again in R&D credit engagements:

 

Treating the credit as an afterthought at filing time, rather than building contemporaneous documentation throughout the year (project notes, time tracking, technical memos). The IRS has increasingly scrutinized claims that rely on after-the-fact reconstruction.

 

Overlooking qualifying activity outside a formal "R&D" team — much of it hides inside product, engineering, or ops functions.

Ignoring state-level credits. Many states offer their own R&D credits with different rules and, notably, different conformity to federal changes like the OBBBA — a state may not have adopted the new federal treatment, so multi-state businesses need to check each jurisdiction rather than assume alignment.

 

Missing the domestic/foreign split now that the two get fundamentally different deduction treatment.

 

The Bottom Line

 

The R&D credit rewards a much broader range of everyday business activity than most owners assume, and the 2025 reinstatement of immediate expensing has made claiming it — correctly, with solid documentation — more valuable than it's been in years. If your business does any kind of iterative product, process, or software development and you haven't had a real conversation about this with your tax advisor recently, it's worth one.